La Jolla, California
United States
41
2024-11-14
30
2025-01-07
These are the the leading inventors for applications assigned to Inhibrx, Inc.:
Inhibrx, Inc. based in La Jolla, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
#2 | 2024-03-28MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME
#3 | 2023-12-28 ✅ Patent 12,187,804 granted on 2025-01-07Multivalent and multispecific 41BB-binding proteins
#4 | 2023-11-02CD28 SINGLE DOMAIN ANTIBODIES AND MULTIVALENT AND MULTISPECIFIC CONSTRUCTS THEREOF
#5 | 2023-10-19Canine PD-1-Binding Polypeptides and Uses Thereof
#6 | 2023-10-05 ✅ Patent 12,084,502 granted on 2024-09-10CD33-binding polypeptides and uses thereof
#7 | 2023-09-21 ✅ Patent 12,331,132 granted on 2025-06-17MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES
#8 | 2023-07-27Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
#9 | 2023-04-27 ✅ Patent 12,012,459 granted on 2024-06-18OX40-binding polypeptides and uses thereof
#10 | 2023-03-02 ✅ Patent 11,919,963 granted on 2024-03-05CD123-binding polypeptides and uses thereof
#11 | 2022-10-13CD33 TARGETED IMMUNOTHERAPIES
#12 | 2022-10-13CLL-1 TARGETED IMMUNOTHERAPIES
#13 | 2022-10-06CD123 TARGETED IMMUNOTHERAPIES
#14 | 2022-05-26 ✅ Patent 11,945,869 granted on 2024-04-02PD-1 single domain antibodies and therapeutic compositions thereof
#15 | 2022-04-07 ✅ Patent 12,227,584 granted on 2025-02-18Multivalent and multispecific OX40-binding fusion proteins
#16 | 2022-03-24Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
#17 | 2022-03-03 ✅ Patent 11,976,126 granted on 2024-05-07Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells
#18 | 2021-12-09 ✅ Patent 12,365,728 granted on 2025-07-22DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
#19 | 2021-01-28 ✅ Patent 11,965,017 granted on 2024-04-23Serpin fusion polypeptides and methods of use thereof
#20 | 2021-01-07 ✅ Patent 11,827,691 granted on 2023-11-28Serpin fusion polypeptides and methods of use thereof
#21 | 2020-11-05 ✅ Patent 11,434,297 granted on 2022-09-06CD123-binding polypeptides and uses thereof
#22 | 2020-11-05 ✅ Patent 12,043,667 granted on 2024-07-23CLEC12a binding polypeptides and uses thereof
#23 | 2020-11-05 ✅ Patent 11,560,428 granted on 2023-01-24CD33-binding polypeptides and uses thereof
#24 | 2020-06-25 ✅ Patent 11,566,078 granted on 2023-01-31PDL1-binding proteins
#25 | 2020-06-18 ✅ Patent 11,208,485 granted on 2021-12-28PD-1 single domain antibodies and therapeutic compositions thereof
#26 | 2020-05-07Non-Immunogenic Single Domain Antibodies
#27 | 2020-04-16 ✅ Patent 11,046,752 granted on 2021-06-29Serpin fusion polypeptides and methods of use thereof
#28 | 2020-02-20 ✅ Patent 11,447,556 granted on 2022-09-20OX40-binding polypeptides and uses thereof
#29 | 2020-02-13 ✅ Patent 12,195,533 granted on 2025-01-14Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
#30 | 2019-11-14 ✅ Patent 10,745,466 granted on 2020-08-18Type III secretion system targeting molecules
#31 | 2019-10-31MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES
#32 | 2019-10-10 ✅ Patent 11,117,973 granted on 2021-09-14Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms
#33 | 2019-08-29 ✅ Patent 11,117,972 granted on 2021-09-14Multivalent and multispecific OX40-binding fusion proteins
#34 | 2019-04-04 ✅ Patent 10,844,129 granted on 2020-11-24Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids
#35 | 2019-01-10 ✅ Patent 11,866,507 granted on 2024-01-09Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
#36 | 2018-06-28 ✅ Patent 10,723,785 granted on 2020-07-28Serpin fusion polypeptides and methods of use thereof
#37 | 2017-07-13 ✅ Patent 10,501,551 granted on 2019-12-10Multivalent and multispecific 41BB-binding fusion proteins
#38 | 2017-01-26 ✅ Patent 10,093,742 granted on 2018-10-09Multispecific GITR-binding fusion proteins and methods of use thereof
#39 | 2017-01-19 ✅ Patent 10,308,720 granted on 2019-06-04Multivalent and multispecific DR5-binding fusion proteins
#40 | 2016-11-03 ✅ Patent 10,344,078 granted on 2019-07-09Type III secretion system targeting molecules
#41 | 2016-07-21 ✅ Patent 10,526,397 granted on 2020-01-07Non-immunogenic single domain antibodies
Also check out Inhibrx, Inc.'s (La Jolla, United States) applicant profile with 26 patent applications submitted.
143880 ⎘